The biotech scorecard for the fourth quarter: 14 stock-moving events to watch

Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the fourth quarter:

Rarely before has a large-cap biotech had so much riding on the outcome of a Phase 2 study as Amgen does with its obesity treatment MariTide, also known as AMG 133. Results are coming before the end of the year.

Novo Nordisk will report results of a Phase 3 study involving its obesity drug candidate CagriSema before the end of this year. CagriSema is a combination of the GLP-1 drug semaglutide, the active ingredient in Ozempic and Wegovy, and cagrilintide, a treatment that activates amylin and calcitonin receptors.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Individual plans

Group plans

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $399/year

$30 for 3 months Get Started

Then $399/year

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

To read the rest of this story subscribe to STAT+.

Subscribe

Log In